Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Cancer: early-phase trial registry
47 of 117 indexed Metastatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #108 of 28,707 conditions by registered trial count.
117 US clinical trials · 47 currently recruiting · #108 of 28,707 conditions by registered trial count
Metastatic Cancer: 117 US clinical trials tracked, 47 recruiting.
Metastatic Cancer is the subject of 117 registered US clinical trials on ClinicalTrials.gov, 47 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition metastatic-cancer
OPEN 47 | RECR 40% | LATE 8 | EARLY 87 | RANK #108 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Knee Osteoarthritis (40% recruiting · 102 trials)
Metastatic Cancer lists 47 open slots (40% of 117 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Cancer is recruiting above its size-band peers.
47 of 117 indexed trials (40.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 11 of 117 trials (9.4%). 80 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 110 trials that report a genuine target (sentinel values excluded). 70 of those (63.6%) plan for fewer than 100 participants.
-
Metastatic Cancer research is mostly interventional.
108 interventional and 9 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
117 total, page 1 of 3
Evaluating Disparities in Precision Oncology
Indiana University
NCT06081517
UNC Metastatic Cancer Radiation Therapy Registry
UNC Lineberger Comprehensive Cancer Center
NCT06306924
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
Alliance Foundation Trials
NCT06963723
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines
NCT05919264
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
UNC Lineberger Comprehensive Cancer Center
NCT06896162
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
M.D. Anderson Cancer Center
NCT06693687
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
NCT05557045
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Duke University
NCT04085029
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
NCT05489237
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
University of Chicago
NCT04295863
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics
NCT05853575
Imaging of Solid Tumors Using FAP-2286
Thomas Hope
NCT04621435
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse
NCT06090266
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience
NCT05267626
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co.
NCT05394103
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT05868226
Prospective Validation of a Points Score System Predicting 30-day Survival
Indiana University
NCT05100342
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics
NCT06533059
Optimizing Y90 Therapy for Radiation Lobectomy
Northwestern University
NCT04390724
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics
NCT05378425
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
NCT07197671
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo
NCT06174987
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
NCT05502315
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Baptist Health South Florida
NCT05789589
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
NCT05010031
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
University of California, Davis
NCT06389123
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
NCT05475171
COBRA: Cancer, Older Adults, Balance and Resistance Activities
Memorial Sloan Kettering Cancer Center
NCT07011862
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
NCT06416007
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06058988
Comparison of Whole Body DWI to FDG PET
University of California, San Francisco
NCT06630845
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
University of Illinois at Chicago
NCT07269080
Definitive Radiation for High-Risk Spine Metastases
Stony Brook University
NCT06165419
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Proviva Therapeutics
NCT06190886
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Washington University School of Medicine
NCT05831579
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT05686226
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT05204147
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
NCT06067503
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Roberto Vargas
NCT05065736
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics
NCT03785249
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences
NCT05208047
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT02711553
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 54 |
| Phase 2 | 33 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Cancer page
117 registered trials, 47 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 47 Metastatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Cancer condition card totals 117 registered trials; most-linked intervention quality-of-life assessment; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.